Ekom Monday Etukudo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ekom Monday Etukudo has a total of 280 co-authors. Here are the top co-authors by number of shared publications:
- Ibe Michael Usman
University of Rwanda, Kigali, Rwanda, Rwanda
7 shared publications - Patrick Maduabuchi Aja
Department of Biochemistry Bushenyi Western Region Kampala International University - Western Campus
6 shared publications Elna Owembabazi
Department of Anatomy Bushenyi Western Region Kampala International University - Western Campus
5 shared publicationsAugustine Oviosun
Department of Anatomy Bushenyi Western Region Kampala International University - Western Campus
4 shared publications- Godson Emeka Anyanwu
Department of Anatomy, Faculty of Biomedical Sciences Bushenyi Western Region Kampala International University - Western Campus
4 shared publications - Ilemobayo Victor Fasogbon
Department of Biochemistry, Faculty of Biomedical Sciences Kampala International University ‐ Western Campus Ishaka Uganda
4 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1642
Multi-Target Neuroprotection by Syzygium aromaticum Ethyl Acetate Fraction Against Mercuric Chloride-Induced Hippocampal Toxicity: Insights from Network Pharmacology, Molecular Docking, and In Vivo Evaluation
Mercury remains a pervasive environmental neurotoxicant strongly implicated in hippocampal oxidative injury and dementia-related cognitive decline, yet safe multi-target agents against its neurotoxicity remain limited. This study investigated the neuroprotective potential of the Syzygium aromaticum (clove) ethyl acetate fraction (SEAF) against mercuric chloride (HgCl 2 )-induced hippocampal neurotoxicity using an integrated network pharmacology, molecular docking, and in vivo evaluations. GC-MS profiling of SEAF (5.29% yield) identified 13 abundant metabolites, dominated by eugenyl acetate, eugenol, 14-hydroxycaryophyllene, and β-caryophyllene. Consensus screening with SwissADME and ADMETlab 3.0 identified eugenyl acetate, benzyl benzoate, and 1-methylcyclododecanol as blood-brain barrier (BBB)-permeant. Network pharmacology integrating SwissTargetPrediction, TargetNet, GeneCards, and the Therapeutic Target Database revealed 16 overlapping dementia-associated targets, with NFKB1 emerging alongside other genes as the principal hub governing nuclear receptor signalling, oxidative stress, and neuroinflammation pathways. Molecular docking against NMDA, GABA_A, NF-κB1, and acetylcholinesterase receptors showed eugenyl acetate and benzyl benzoate consistently exhibited the strongest and most consistent binding affinities among the BBB-permeant metabolites. In vivo , pretreatment with SEAF (250–1000 mg/kg) dose-dependently attenuated HgCl₂-induced deficits in object location and Y-maze performance, restored hippocampal superoxide dismutase and catalase activities, reduced malondialdehyde levels, and preserved CA1/CA3 pyramidal cell architecture, with the 1000 mg/kg dose approximating Vitamin E and control groups. These convergent computational and experimental findings identify SEAF as a multi-target neuroprotective agent that mitigates mercury-induced hippocampal neurodegeneration through coordinated antioxidant, anti-inflammatory, and neurotransmission-modulating mechanisms, supporting its further development as a candidate nutraceutical neuroprotectant against heavy-metal-associated dementia risk.
- 5 October 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1642
Open AccessMulti-Target Neuroprotection by Syzygium aromaticum Ethyl Acetate Fraction Against Mercuric Chloride-Induced Hippocampal Toxicity: Insights from Network Pharmacology, Molecular Docking, and In Vivo Evaluation
Mercury remains a pervasive environmental neurotoxicant strongly implicated in hippocampal oxidative injury and dementia-related cognitive decline, yet safe multi-target agents against its neurotoxicity remain limited. This study investigated the neuroprotective potential of the Syzygium aromaticum (clove) ethyl acetate fraction (SEAF) against mercuric chloride (HgCl 2 )-induced hippocampal neurotoxicity using an integrated network pharmacology, molecular docking, and in vivo evaluations. GC-MS profiling of SEAF (5.29% yield) identified 13 abundant metabolites, dominated by eugenyl acetate, eugenol, 14-hydroxycaryophyllene, and β-caryophyllene. Consensus screening with SwissADME and ADMETlab 3.0 identified eugenyl acetate, benzyl benzoate, and 1-methylcyclododecanol as blood-brain barrier (BBB)-permeant. Network pharmacology integrating SwissTargetPrediction, TargetNet, GeneCards, and the Therapeutic Target Database revealed 16 overlapping dementia-associated targets, with NFKB1 emerging alongside other genes as the principal hub governing nuclear receptor signalling, oxidative stress, and neuroinflammation pathways. Molecular docking against NMDA, GABA_A, NF-κB1, and acetylcholinesterase receptors showed eugenyl acetate and benzyl benzoate consistently exhibited the strongest and most consistent binding affinities among the BBB-permeant metabolites. In vivo , pretreatment with SEAF (250–1000 mg/kg) dose-dependently attenuated HgCl₂-induced deficits in object location and Y-maze performance, restored hippocampal superoxide dismutase and catalase activities, reduced malondialdehyde levels, and preserved CA1/CA3 pyramidal cell architecture, with the 1000 mg/kg dose approximating Vitamin E and control groups. These convergent computational and experimental findings identify SEAF as a multi-target neuroprotective agent that mitigates mercury-induced hippocampal neurodegeneration through coordinated antioxidant, anti-inflammatory, and neurotransmission-modulating mechanisms, supporting its further development as a candidate nutraceutical neuroprotectant against heavy-metal-associated dementia risk.
- Open Access
- 14 July 2026
- Published by Elsevier in Phytomedicine Plus
- Vol. 6 (3)
A systematic review of the fertility-enhancing effects of Garcinia kola and its metabolites: Evidence from in vivo rodent studies
- 14 July 2026
- Published by Elsevier in Phytomedicine Plus
- Vol. 6 (3)
Open AccessA systematic review of the fertility-enhancing effects of Garcinia kola and its metabolites: Evidence from in vivo rodent studies
- Open Access
- 20 February 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Exploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method A literature search was conducted across PubMed, Scopus, and Google Scholar for articles published up to June 2024 using PRISMA 2020 guidelines. Eligible studies involve preclinical models of BPH, interventions specifically targeting plant or plant-based therapy, quantitative outcomes related to BPH treatment and ameliorations, and studies with clear methodology and reporting of the administration and plant-based products. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.
- 20 February 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Open AccessExploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method A literature search was conducted across PubMed, Scopus, and Google Scholar for articles published up to June 2024 using PRISMA 2020 guidelines. Eligible studies involve preclinical models of BPH, interventions specifically targeting plant or plant-based therapy, quantitative outcomes related to BPH treatment and ameliorations, and studies with clear methodology and reporting of the administration and plant-based products. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (3) , 608-633
The Global State of Contemporary Andrology Practice: A Comprehensive Analysis of Clinical Practice, Training Pathways, and Emerging Challenges
Shah R, et al. World J Mens Health. 2025 Jun;43:e41. https://doi.org/10.5534/wjmh.250039
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (3) , 608-633
Open AccessThe Global State of Contemporary Andrology Practice: A Comprehensive Analysis of Clinical Practice, Training Pathways, and Emerging Challenges
Shah R, et al. World J Mens Health. 2025 Jun;43:e41. https://doi.org/10.5534/wjmh.250039
- Open Access
- 16 September 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 931
Plant-based management of Iron Deficiency Anemia (IDA) in East Africa community: a systematic review
Background Iron Deficiency Anaemia (IDA) is a major public health challenge in East Africa, particularly affecting children and women. Conventional therapies are often limited by accessibility and cost, prompting interest in plant-based interventions as affordable and locally available alternatives. This review explores the potential of medicinal plants in managing IDA, focusing on their phytochemical composition, mechanisms of action, and haematological effects. Methods A systematic search of PubMed, Scopus, and Web of Science databases was conducted on July 17, 2024. The search strategy utilised Boolean operators and keywords related to plants, IDA management, and East Africa. Studies meeting inclusion criteria were peer-reviewed articles published in English that evaluated plant-based treatments for IDA in preclinical or clinical trials. A total of 30 eligible studies were included after screening and quality assessment following PRISMA guidelines. Results The review identified plants such as Moringa oleifera , Phyllanthus emblica , and Telfairia occidentalis as effective in improving haemoglobin levels, red blood cell counts, and other haematological indices. Mechanisms include enhanced iron absorption, antioxidant activity, and stimulation of haematopoiesis. Extraction techniques commonly used were high-performance liquid chromatography (HPLC) and aqueous methods. Key phytochemicals like flavonoids, saponins, and phenolic compounds played critical roles in IDA management. Despite promising outcomes, variations in treatment duration and protocols were noted, highlighting the need for standardisation. Conclusion Plant-based therapies offer accessible, cost-effective solutions for managing IDA in East Africa, leveraging local resources and phytochemical properties. However, further pharmacological and toxicological studies are essential to confirm safety and efficacy. This review emphasises the potential of medicinal plants in addressing IDA and calls for the exploration of underutilised plant species and the development of standardised therapeutic protocols.
- 16 September 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 931
Open AccessPlant-based management of Iron Deficiency Anemia (IDA) in East Africa community: a systematic review
Background Iron Deficiency Anaemia (IDA) is a major public health challenge in East Africa, particularly affecting children and women. Conventional therapies are often limited by accessibility and cost, prompting interest in plant-based interventions as affordable and locally available alternatives. This review explores the potential of medicinal plants in managing IDA, focusing on their phytochemical composition, mechanisms of action, and haematological effects. Methods A systematic search of PubMed, Scopus, and Web of Science databases was conducted on July 17, 2024. The search strategy utilised Boolean operators and keywords related to plants, IDA management, and East Africa. Studies meeting inclusion criteria were peer-reviewed articles published in English that evaluated plant-based treatments for IDA in preclinical or clinical trials. A total of 30 eligible studies were included after screening and quality assessment following PRISMA guidelines. Results The review identified plants such as Moringa oleifera , Phyllanthus emblica , and Telfairia occidentalis as effective in improving haemoglobin levels, red blood cell counts, and other haematological indices. Mechanisms include enhanced iron absorption, antioxidant activity, and stimulation of haematopoiesis. Extraction techniques commonly used were high-performance liquid chromatography (HPLC) and aqueous methods. Key phytochemicals like flavonoids, saponins, and phenolic compounds played critical roles in IDA management. Despite promising outcomes, variations in treatment duration and protocols were noted, highlighting the need for standardisation. Conclusion Plant-based therapies offer accessible, cost-effective solutions for managing IDA in East Africa, leveraging local resources and phytochemical properties. However, further pharmacological and toxicological studies are essential to confirm safety and efficacy. This review emphasises the potential of medicinal plants in addressing IDA and calls for the exploration of underutilised plant species and the development of standardised therapeutic protocols.
- Open Access
- 21 July 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 716
THE PROTECTIVE ROLE OF FLAVONOIDS IN AMNESIA -SYSTEMATIC REVIEW
Background Amnesia, a debilitating memory disorder, often arises from neurodegenerative diseases, oxidative stress, and synaptic dysfunction. Current therapies offer limited efficacy and are associated with adverse effects, prompting exploration of safer neuroprotective agents. Flavonoids, abundant in fruits, vegetables, and medicinal plants, have emerged as promising candidates due to their antioxidant, anti-inflammatory, and neurotrophic properties. Objective This systematic review critically evaluated experimental evidence on the protective role of flavonoids in amnesia, highlighting their mechanisms of action, therapeutic outcomes, and translational potential. Methods A comprehensive literature search was conducted using structured search strategies across the Web of Science, Scopus, and PubMed databases. Studies published between 2010 and 2024 were screened according to PRISMA 2020 guidelines. Only original experimental research investigating flavonoid interventions in animal models of amnesia was included. Results Out of 593 retrieved articles, 25 studies met the inclusion criteria. Behavioral assessments predominantly employed the Morris Water Maze, Novel Object Recognition Test, and Y-Maze to evaluate cognitive performance. Flavonoid interventions consistently improved memory functions, reduced oxidative stress markers (MDA), enhanced antioxidant defenses (GSH, SOD, CAT), and modulated neuroprotective gene expressions (BDNF, CREB1, Nrf2). Both crude plant extracts and isolated flavonoids, administered primarily via oral routes, demonstrated robust efficacy. Animal models included Swiss albino mice, Wistar rats, and zebrafish. Conclusions Flavonoids exhibit multi-targeted neuroprotection against amnesia by enhancing synaptic plasticity, combating oxidative damage, and modulating apoptotic pathways. These findings support advancing flavonoids toward clinical applications for cognitive disorders, warranting further translational studies and optimized formulations.
- 21 July 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 716
Open AccessTHE PROTECTIVE ROLE OF FLAVONOIDS IN AMNESIA -SYSTEMATIC REVIEW
Background Amnesia, a debilitating memory disorder, often arises from neurodegenerative diseases, oxidative stress, and synaptic dysfunction. Current therapies offer limited efficacy and are associated with adverse effects, prompting exploration of safer neuroprotective agents. Flavonoids, abundant in fruits, vegetables, and medicinal plants, have emerged as promising candidates due to their antioxidant, anti-inflammatory, and neurotrophic properties. Objective This systematic review critically evaluated experimental evidence on the protective role of flavonoids in amnesia, highlighting their mechanisms of action, therapeutic outcomes, and translational potential. Methods A comprehensive literature search was conducted using structured search strategies across the Web of Science, Scopus, and PubMed databases. Studies published between 2010 and 2024 were screened according to PRISMA 2020 guidelines. Only original experimental research investigating flavonoid interventions in animal models of amnesia was included. Results Out of 593 retrieved articles, 25 studies met the inclusion criteria. Behavioral assessments predominantly employed the Morris Water Maze, Novel Object Recognition Test, and Y-Maze to evaluate cognitive performance. Flavonoid interventions consistently improved memory functions, reduced oxidative stress markers (MDA), enhanced antioxidant defenses (GSH, SOD, CAT), and modulated neuroprotective gene expressions (BDNF, CREB1, Nrf2). Both crude plant extracts and isolated flavonoids, administered primarily via oral routes, demonstrated robust efficacy. Animal models included Swiss albino mice, Wistar rats, and zebrafish. Conclusions Flavonoids exhibit multi-targeted neuroprotection against amnesia by enhancing synaptic plasticity, combating oxidative damage, and modulating apoptotic pathways. These findings support advancing flavonoids toward clinical applications for cognitive disorders, warranting further translational studies and optimized formulations.
- Open Access
- 9 July 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (13) , e70439
Neurophysiological mechanisms underlying cardiovascular adaptations to exercise: A narrative review
The brain–heart connection, particularly during physical activity, plays a crucial role in health and disease management. This review examined the neurophysiological mechanisms driving cardiovascular adaptations to exercise, focusing on the bidirectional relationship between the brain and heart. Key mediators such as central autonomic networks, brain‐derived neurotrophic factors (BDNF), and vascular endothelial growth factor (VEGF) enhance neural plasticity and vascular health. Regular structured exercise (e.g., high‐intensity interval training, moderate and resistance exercise) moderates autonomic responses, increases BDNF, and supports neurovascular coupling, improving both cognitive and cardiovascular resilience through molecular pathways such as PGC‐1α and TrkB signaling. Exercise enhances cerebral perfusion, reduces oxidative stress, and protects brain–heart health. It mitigates risks linked to neurodegenerative diseases, such as Alzheimer's and Parkinson's, by promoting neuroplasticity and vascular integrity. This review highlights the importance of incorporating exercise‐based interventions in clinical practice and public health policies to optimize cognitive and cardiovascular health. Future studies should explore exercise‐induced neurovascular coupling to further elucidate the mechanisms connecting brain and cardiovascular health.
- 9 July 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (13) , e70439
Open AccessNeurophysiological mechanisms underlying cardiovascular adaptations to exercise: A narrative review
The brain–heart connection, particularly during physical activity, plays a crucial role in health and disease management. This review examined the neurophysiological mechanisms driving cardiovascular adaptations to exercise, focusing on the bidirectional relationship between the brain and heart. Key mediators such as central autonomic networks, brain‐derived neurotrophic factors (BDNF), and vascular endothelial growth factor (VEGF) enhance neural plasticity and vascular health. Regular structured exercise (e.g., high‐intensity interval training, moderate and resistance exercise) moderates autonomic responses, increases BDNF, and supports neurovascular coupling, improving both cognitive and cardiovascular resilience through molecular pathways such as PGC‐1α and TrkB signaling. Exercise enhances cerebral perfusion, reduces oxidative stress, and protects brain–heart health. It mitigates risks linked to neurodegenerative diseases, such as Alzheimer's and Parkinson's, by promoting neuroplasticity and vascular integrity. This review highlights the importance of incorporating exercise‐based interventions in clinical practice and public health policies to optimize cognitive and cardiovascular health. Future studies should explore exercise‐induced neurovascular coupling to further elucidate the mechanisms connecting brain and cardiovascular health.
- Open Access
- 9 July 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 680
Unveiling the Fertility Potential of Brassica oleracea: In Silico and In vivo Insights into Protein Kinase B (PKB/AKT1) and Epidermal Growth Factor Receptor (EGFR) Inhibition
Background Infertility is a global health issue, with male factor infertility contributing to nearly 50% of cases. Dysregulation of Protein Kinase B (PKB/AKT1) and Epidermal Growth Factor Receptor (EGFR) signaling impairs spermatogenesis. Bioactive compounds offer promising alternatives for targeting these pathways. Brassica oleracea var. viridis (collard greens) contains phytochemicals with antioxidant and anti-inflammatory properties, suggesting potential reproductive benefits. Objective This study evaluates bioactive compounds from B. oleracea var. viridis as AKT1 and EGFR inhibitors through molecular docking and in vivo validation in a cimetidine (Cemet ®)-induced reproductive toxicity model. Methods Bioactive compounds were identified via Gas Chromatography-Mass Spectrometry and analyzed for physicochemical, pharmacokinetic, and pharmacodynamic properties. Molecular docking assessed binding affinity to AKT1 and EGFR, followed by in vivo validation in cimetidine-exposed Wistar rats. Effects of ethanol extracts and solvent fractions on sperm motility, viability, morphology, count, and agglutination were examined. Results Gamma-sitosterol showed the strongest binding affinity to AKT1 (-8.0 kcal/mol) and EGFR (-6.5 kcal/mol), comparable to co-crystallized ligands. Computational analysis indicated high Gastro-intestinal absorption and low toxicity for most compounds. In vivo, B. oleracea extracts significantly improved sperm motility, viability, and count, mitigating cimetidine-induced toxicity. Ethanol Leaf Extract of Brassica Oleracea (ELEBO), AFBO (Aqueous fractions of brassica Oleracea) and BFBO (n- Butanol fractions of brassica Oleracea) fractions had the most pronounced protective effects, reducing sperm abnormalities and agglutination. Conclusion B. oleracea var. viridis bioactive compounds show spermatoprotective effects, likely via AKT1 and EGFR inhibition. These findings support further research into B. oleracea derivatives for male reproductive health applications.
- 9 July 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 680
Open AccessUnveiling the Fertility Potential of Brassica oleracea: In Silico and In vivo Insights into Protein Kinase B (PKB/AKT1) and Epidermal Growth Factor Receptor (EGFR) Inhibition
Background Infertility is a global health issue, with male factor infertility contributing to nearly 50% of cases. Dysregulation of Protein Kinase B (PKB/AKT1) and Epidermal Growth Factor Receptor (EGFR) signaling impairs spermatogenesis. Bioactive compounds offer promising alternatives for targeting these pathways. Brassica oleracea var. viridis (collard greens) contains phytochemicals with antioxidant and anti-inflammatory properties, suggesting potential reproductive benefits. Objective This study evaluates bioactive compounds from B. oleracea var. viridis as AKT1 and EGFR inhibitors through molecular docking and in vivo validation in a cimetidine (Cemet ®)-induced reproductive toxicity model. Methods Bioactive compounds were identified via Gas Chromatography-Mass Spectrometry and analyzed for physicochemical, pharmacokinetic, and pharmacodynamic properties. Molecular docking assessed binding affinity to AKT1 and EGFR, followed by in vivo validation in cimetidine-exposed Wistar rats. Effects of ethanol extracts and solvent fractions on sperm motility, viability, morphology, count, and agglutination were examined. Results Gamma-sitosterol showed the strongest binding affinity to AKT1 (-8.0 kcal/mol) and EGFR (-6.5 kcal/mol), comparable to co-crystallized ligands. Computational analysis indicated high Gastro-intestinal absorption and low toxicity for most compounds. In vivo, B. oleracea extracts significantly improved sperm motility, viability, and count, mitigating cimetidine-induced toxicity. Ethanol Leaf Extract of Brassica Oleracea (ELEBO), AFBO (Aqueous fractions of brassica Oleracea) and BFBO (n- Butanol fractions of brassica Oleracea) fractions had the most pronounced protective effects, reducing sperm abnormalities and agglutination. Conclusion B. oleracea var. viridis bioactive compounds show spermatoprotective effects, likely via AKT1 and EGFR inhibition. These findings support further research into B. oleracea derivatives for male reproductive health applications.
- Open Access
- 8 April 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Exploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.
- 8 April 2025
- Published by F1000 Research Ltd in F1000Research
- Vol. 14, 412
Open AccessExploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review
Background Benign prostatic hyperplasia [BPH] is a prevalent condition among aging men, characterized by prostate gland enlargement leading to lower urinary tract symptoms [LUTS]. Conventional treatments like alpha-blockers and 5-alpha-reductase inhibitors, though effective, often result in adverse effects. This has spurred interest in phytotherapy, leveraging plant-derived compounds to mitigate BPH symptoms due to their safety, cost-effectiveness, and patient preference. Method The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Results The review highlighted 84 studies involving diverse plants and bioactive compounds. Prominent examples include Serenoa repens [saw palmetto], Urtica dioica [nettle root], Cucurbita pepo [pumpkin seed], and Pygeum africanum [African cherry]. These plants exhibit mechanisms such as 5α-reductase inhibition, anti-inflammatory effects, and modulation of oxidative stress. Clinical and preclinical findings demonstrate improved urinary flow, reduced prostate volume, and alleviated LUTS. However, variability in methodologies, extract preparations, and dosages poses challenges to standardization. Conclusion Phytotherapy holds significant potential in BPH management, offering symptom relief with minimal side effects. While promising, further robust clinical trials are essential to validate efficacy, establish standardized protocols, and ensure integration into mainstream therapeutic frameworks.